---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-070158"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:54:25.681283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences reports FY 2023 net loss of $31.5M; FB-102 advances to MAD cohort

## Summary
- Net loss of $31.5M ($1.00 per share) vs. $13.9M ($0.80) in FY 2022, driven by increased R&D spend.
- R&D expenses rose to $21.9M from $5.6M, primarily due to FB-102 manufacturing and clinical costs.
- Cash and equivalents of $37.1M at year-end 2023, down from $41.1M at end of 2022.
- FB-102 Phase 1 SAD portion completed; multiple ascending dose (MAD) cohorts now dosing.
- Shares outstanding of 36.3M as of Dec 31, 2023.

## SEC filing metadata
- accession: 0001193125-24-070158
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/0001193125-24-070158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/d784785d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-070158
- JSON: https://secwatch.observer/filing/0001193125-24-070158.json
- Plain text: https://secwatch.observer/filing/0001193125-24-070158.txt

## Key facts
- Earnings Releases
  Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income $ (31,476 ), EPS $ (1.00 ).
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Net income: $ (31,476 )
  - EPS: $ (1.00 )
  - Result: reported results
  source text: On March 18, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/0001193125-24-070158-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.